Edgewise Therapeutics Advances EDG-7500 to Phase 3 Following 'Positive' HCM Data

MT Newswires Live06-16

Edgewise Therapeutics (EWTX) phase 2 Cirrus-HCM trial of EDG-7500 met key efficacy and safety endpoints in obstructive and non-obstructive hypertrophic cardiomyopathy, supporting advancement to Phase 3, the company said Tuesday.

The 12-week study showed clinically meaningful improvements in echocardiogram measures, biomarkers, symptoms and functional status across both groups, including 90% of obstructive HCM patients with hemodynamic improvement and significant reductions in NT-proBNP and quality-of-life scores across cohorts.

Edgewise said EDG-7500 was generally well tolerated, with no new safety signals, no meaningful reductions in LVEF below 50% and no observed relationship between drug exposure and LVEF changes.

The company said it plans to initiate a Phase 3 program in Q4 2026.

Edgewise Therapeutics shares were down more than 24% in premarket activity Tuesday.

Price: 26.50, Change: -8.71, Percent Change: -24.74

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643754540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643754540","market":"sg","top_or_hot":-1,"title":"Edgewise Therapeutics Advances EDG-7500 to Phase 3 Following 'Positive' HCM Data","media":"MT Newswires Live","content":"<html><body><p> Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) phase 2 Cirrus-HCM trial of EDG-7500 met key efficacy and safety endpoints in obstructive and non-obstructive hypertrophic cardiomyopathy, supporting advancement to Phase 3, the company said Tuesday.</p><p>The 12-week study showed clinically meaningful improvements in echocardiogram measures, biomarkers, symptoms and functional status across both groups, including 90% of obstructive HCM patients with hemodynamic improvement and significant reductions in NT-proBNP and quality-of-life scores across cohorts.</p><p>Edgewise said EDG-7500 was generally well tolerated, with no new safety signals, no meaningful reductions in LVEF below 50% and no observed relationship between drug exposure and LVEF changes.</p><p>The company said it plans to initiate a Phase 3 program in Q4 2026.</p><p>Edgewise Therapeutics shares were down more than 24% in premarket activity Tuesday.</p><p>Price: 26.50, Change: -8.71, Percent Change: -24.74</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics Advances EDG-7500 to Phase 3 Following 'Positive' HCM Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics Advances EDG-7500 to Phase 3 Following 'Positive' HCM Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-16 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) phase 2 Cirrus-HCM trial of EDG-7500 met key efficacy and safety endpoints in obstructive and non-obstructive hypertrophic cardiomyopathy, supporting advancement to Phase 3, the company said Tuesday.</p><p>The 12-week study showed clinically meaningful improvements in echocardiogram measures, biomarkers, symptoms and functional status across both groups, including 90% of obstructive HCM patients with hemodynamic improvement and significant reductions in NT-proBNP and quality-of-life scores across cohorts.</p><p>Edgewise said EDG-7500 was generally well tolerated, with no new safety signals, no meaningful reductions in LVEF below 50% and no observed relationship between drug exposure and LVEF changes.</p><p>The company said it plans to initiate a Phase 3 program in Q4 2026.</p><p>Edgewise Therapeutics shares were down more than 24% in premarket activity Tuesday.</p><p>Price: 26.50, Change: -8.71, Percent Change: -24.74</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643754540","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643754540","pubTimestamp":1781610370,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Edgewise Therapeutics  phase 2 Cirrus-HCM trial of EDG-7500 met key efficacy and safety endpoints in obstructive and non-obstructive hypertrophic cardiomyopathy, supporting advancement to Phase 3, the company said Tuesday.The 12-week study showed clinically meaningful improvements in echocardiogram measures, biomarkers, symptoms and functional status across both groups, including 90% of obstructive HCM patients with hemodynamic improvement and significant reductions in NT-proBNP and quality-of-life scores across cohorts.Edgewise said EDG-7500 was generally well tolerated, with no new safety signals, no meaningful reductions in LVEF below 50% and no observed relationship between drug exposure and LVEF changes.The company said it plans to initiate a Phase 3 program in Q4 2026.Edgewise Therapeutics shares were down more than 24% in premarket activity Tuesday.Price: 26.50, Change: -8.71, Percent Change: -24.74","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HCM":"和黄医药","BK4531":"中概回港概念","BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"Edgewise Therapeutics根据“积极”HCM数据将EDG-7500推进至3期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1.5,"HCM":1.5},"content_text":"Edgewise Therapeutics (EWTX) phase 2 Cirrus-HCM trial of EDG-7500 met key efficacy and safety endpoints in obstructive and non-obstructive hypertrophic cardiomyopathy, supporting advancement to Phase 3, the company said Tuesday.The 12-week study showed clinically meaningful improvements in echocardiogram measures, biomarkers, symptoms and functional status across both groups, including 90% of obstructive HCM patients with hemodynamic improvement and significant reductions in NT-proBNP and quality-of-life scores across cohorts.Edgewise said EDG-7500 was generally well tolerated, with no new safety signals, no meaningful reductions in LVEF below 50% and no observed relationship between drug exposure and LVEF changes.The company said it plans to initiate a Phase 3 program in Q4 2026.Edgewise Therapeutics shares were down more than 24% in premarket activity Tuesday.Price: 26.50, Change: -8.71, Percent Change: -24.74","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643754540","isCrawlerRequest":true}